1. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial
    A. Demols et al, 2020, Annals of Oncology CrossRef
  2. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma
    Ibrahim Halil Sahin et al, 2021, Expert Opinion on Investigational Drugs CrossRef
  3. Patient-Derived Organoids of Cholangiocarcinoma
    Christopher Fabian Maier et al, 2021, International Journal of Molecular Sciences CrossRef

  4. Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma


    Guohe Lin et al, 2020, Cancer Management and Research CrossRef
  5. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
    Weijing Sun et al, 2019, Cancer CrossRef
  6. Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy
    Elisa Lozano et al, 2019, Hepatology CrossRef
  7. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma
    Tao Peng et al, 2019, International Journal of Oncology CrossRef
  8. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium
    Alessandra Gentilini et al, 2018, International Journal of Molecular Sciences CrossRef
  9. Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment
    Michael Koch et al, 2022, Cells CrossRef
  10. Autophagy activity in cholangiocarcinoma is associated with anatomical localization of the tumor
    Gábor Lendvai et al, 2021, PLOS ONE CrossRef
  11. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
    Riccardo Carloni et al, 2022, Translational Oncology CrossRef
  12. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
    Elena V. Poddubskaya et al, 2018, Experimental Hematology & Oncology CrossRef
  13. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
    Jose J. G. Marin et al, 2021, Cancers CrossRef
  14. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature
    Yuka Futsukaichi et al, 2019, Clinical Journal of Gastroenterology CrossRef
  15. The Tumor Environment: Cholangiocarcinoma-Associated Fibroblasts and Beyond
    Anja Moncsek et al, 2021, Diagnosis and Management of Cholangiocarcinoma CrossRef
  16. The role of metabolic reprogramming in liver cancer and its clinical perspectives
    Mengxiao Lu et al, 2024, Frontiers in Oncology CrossRef